Autres langues SpectraCure AB

Actions

SPEC

SE0007158118

Marché Fermé - Nasdaq Stockholm Autres places de cotation 17:29:57 26/04/2024			Varia. 5j.	Varia. 1 janv.
2,87 ^SEK	+5,32 %		+9,54 %	-25,65 %

23/02	Spectracure AB (Publ) poursuit le processus d'initiation d'une étude clinique pour le cancer de la prostate localisé primaire	CI
22/02	SpectraCure AB (publ) annonce ses résultats pour le quatrième trimestre et l'exercice clos le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

SpectraCure takes the next step in the work with the new clinical study	23/02
Spectracure AB Continues in the Process of Initiating A Clinical Study, for Primary Localised Prostate Cancer	23/02
SpectraCure AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	22/02
A well-accomplished annual audit in accordance with ISO 13485:2016	23/01
Expert group comments on results of ongoing study	19/12
SpectraCure AB Conducts a Clinical Study for Patients with Recurrence of Prostate Cancer After Radiotherapy	19/12
SpectraCure : Masoud Khayyami presents SpectraCure at investor meetingon November 5 in Lund!	29/11
SpectraCure AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	16/11
SpectraCure has decided to seek approval for a clinical study of primary prostate cancer	16/11
SpectraCure AB Decides to Seek Approval for Clinical Study of Primary Prostate Cancer	16/11
SpectraCure : Meet SpectraCure’s board member, Homer Pien!	31/10/23
SpectraCure strengthens presence among urologists	06/10/23
SpectraCure AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	17/08/23
SpectraCure has been awarded an additional EU grant for industrialisation of the company's treatment system Q-PRO®	27/06/23
SpectraCure Receives an Additional EU Grant	27/06/23
SpectraCure AB Reports Earnings Results for the First Quarter Ended March 31, 2023	16/05/23
SpectraCure AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	22/02/23
SpectraCures signs Letter of Intent with Cheplapharm	07/12/22
SpectraCures Signs Letter of Intent with Cheplapharm	07/12/22
SpectraCure : First treatment with Q-PRO and integrated image management technology	25/11/22

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues SpectraCure AB

Actions

SPEC

SE0007158118

Autres langues

Filtres